Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists watch EBV wake up in healthy young people

NCT ID NCT07536048

Knowledge-focused Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 100 healthy adults aged 18 to 29 who have had Epstein-Barr virus (EBV) in the past. Researchers collect blood and saliva samples over 6 to 12 months to see when the virus becomes active again and how the immune system responds. No treatments or vaccines are given—the goal is simply to gather information.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help researchers understand why EBV reactivates and how the immune system responds, potentially guiding future treatments or vaccines.
What could go wrong
This is an observational study with no intervention, so it won't directly test any treatment. It is small (100 participants) and only follows people for up to a year, which may limit how much we learn.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Approximately 100 EBV seropositive participants aged 18 to 29 years

Ages

18 to 29 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 29 years on the day of inclusion * Participants who are healthy as determined by medical evaluation including medical history and physical examination * Participants who are EBV seropositive based on serology testing Exclusion Criteria: Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives, including planning to leave the area of the study before the end of study period The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epstein-Barr virus (EBV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epstein-Barr virus (EBV) Healthy volunteers

Contacts and locations

Locations

  • Griffith - University Clinical Trial Unit - Site Number : 0360001

    Gold Coast, 4222, Australia

  • University of Sunshine Coast - Site Number : 0360002

    South Brisbane, 4101, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.